Conclusion
DISEASE
The viral load reduction of ORF1ab, N Protein and S Protein genes at day 4, with the treatment with domperidone or placebo, was not significantly different as resulted in this clinical trial. From the results of this study, no information for the recommendation of the use of domperidone as antiviral for treating patients with mild-to-moderate COVID-19 was obtained.Further research is needed to explore whether a higher dose of domperidone than used in this study might provide the expected antiviral action and also needs more investigation if the administration of the drug for more than 7 days might improve the clinical results, or if the use as preventive might avoid the disease instauration.